A Phase 1/2 interventional study of XPF-001 and Placebo in Primary Erythromelalgia and Inherited Erythromelalgia, sponsored by Xenon Pharmaceuticals Inc.. Completed at 1 site in Netherlands. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2012-03-16.
Sponsored by Xenon Pharmaceuticals Inc. · Phase 1/2, Interventional, and Treatment
The purpose of this study is to determine whether XPF-001 is safe and effective in the treatment of pain caused by Inherited Erythromelalgia (IEM).
Xenon Pharmaceuticals Inc. is the lead sponsor of 23 studies on the registry; 8 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study requires you to:
Your role in the study includes:
Exclusion Criteria:
Drug: Placebo
Drug: XPF-001
Oral capsule
Oral capsule
Pain intensity difference (PID) in each treatment period based on an 11-point Pain Intensity-NRS (where 0 = No pain and 10 = worst pain you can imagine)
Time frame: 2 days
This study is completed, as verified in Mar 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Erythromelalgia
Xenon Pharmaceuticals Inc.